Maze Therapeutics, Inc. (MAZE)
NASDAQ: MAZE · Real-Time Price · USD
25.82
-0.65 (-2.46%)
At close: Apr 28, 2026, 4:00 PM EDT
25.95
+0.13 (0.50%)
After-hours: Apr 28, 2026, 4:10 PM EDT
Maze Therapeutics Employees
Maze Therapeutics had 141 employees as of December 31, 2025. The number of employees increased by 16 or 12.80% compared to the previous year.
Employees
141
Change (1Y)
16
Growth (1Y)
12.80%
Revenue / Employee
n/a
Profits / Employee
-$929,929
Market Cap
1.43B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 141 | 16 | 12.80% |
| Dec 31, 2024 | 125 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Iovance Biotherapeutics | 975 |
| Immatics | 711 |
| Agios Pharmaceuticals | 540 |
| Immunocore Holdings | 524 |
| Ardelyx | 489 |
| Biohaven | 274 |
| Viridian Therapeutics | 252 |
| Precigen | 160 |
MAZE News
- 6 days ago - Maze Therapeutics Announces $150 Million Registered Offering - GlobeNewsWire
- 4 weeks ago - MAZE Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses - GlobeNewsWire
- 4 weeks ago - Maze Therapeutics Stock Falls Despite Strong Phase 2 Kidney Drug Data For MZE829 - Benzinga
- 4 weeks ago - Maze Therapeutics Transcript: Study result - Transcripts
- 4 weeks ago - Maze Therapeutics Announces Positive Topline Data from Phase 2 HORIZON Trial of MZE829 Demonstrating the First Clinical Proof-of-Concept in Patients with Broad APOL1-Mediated Kidney Disease - GlobeNewsWire
- 4 weeks ago - Maze Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Highlights - GlobeNewsWire
- 7 weeks ago - Maze Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference - Transcripts
- 2 months ago - Maze Therapeutics to Participate in the TD Cowen 46th Annual Health Care Conference - GlobeNewsWire